Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study-Reference-Cited by-同舟云学术

Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study

Published:2016-05-19 Issue:5 Volume:11 Page:e0155842
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Neukam Karin,Espinosa Nuria,Collado Antonio,Delgado-Fernández Marcial,Jiménez-Aguilar Patricia,Rivero-Juárez Antonio,Hontañón-Antoñana Victor,Gómez-Berrocal Ana,Ruiz-Morales Josefa,Merino Dolores,Carrero Ana,Téllez Francisco,Ríos María José,Hernández-Quero José,de Lagarde-Sebastián María,Pérez-Camacho Inés,Vera-Méndez Francisco,Macías Juan,Pineda Juan A.,

Funder

Gilead Sciences

Instituto de Salud Carlos III

Junta de Andalucía

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference24 articles.

1. HAART and the liver: friend or foe?;JA Pineda;Eur J Med Res,2010

2. Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort;A Di Biagio;HIV Clin Trials,2014

3. Hepatic safety profile of fosamprenavir-containing regimens in HIV-1-infected patients with or without hepatitis B or C coinfection;B Ha;HIV Clin Trials,2012